Birchview Capital’s Inhibrx INBX Stock Holding History

Birchview Capital’s Portfolio INBX Stock Details INBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-3,698	Closed	-$292K	–	77
2025 Q4	$292K	Sell	3,698 -28,000	-88%	-$1.91M	0.17%	62
2025 Q3	$1.07M	Sell	31,698 -412	-1%	-$10.1K	0.81%	34
2025 Q2	$458K	Hold	32,110	–	–	0.46%	45
2025 Q1	$449K	Hold	32,110	–	–	0.39%	35
2024 Q4	$494K	Hold	32,110	–	–	0.4%	33
2024 Q3	$503K	Buy	32,110 +20,000	+165%	+$281K	0.44%	30
2024 Q2	$171K	Buy	+12,110	New	+$189K	0.16%	51

Other funds holding INBX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Birchview Capital's INBX Position: Q1 2026 in Review

Birchview Capital sold out of Inhibrx (INBX) in Q1 2026, closing a stake of 3,698 shares — an estimated $292K sold.

Birchview Capital first reported a position in INBX in Q2 2024 and held it in 7 quarters. The position peaked at $1.07M in Q3 2025. 135 funds tracked by Wall St. Rank hold INBX as of Q1 2026.

Birchview Capital reported no remaining Inhibrx position as of Q1 2026 after selling out during the quarter.
Birchview Capital sold 3,698 Inhibrx shares in Q1 2026, an estimated $292K.
Birchview Capital first reported a position in Inhibrx in Q2 2024 and held it in 7 quarters.
Birchview Capital's Inhibrx position peaked at $1.07M in Q3 2025.
135 funds tracked by Wall St. Rank held Inhibrx as of Q1 2026.

Based on Birchview Capital's 13F filing for Q1 2026, filed 15 May 2026.